KLRK1 and neoplasm: Different activating receptors confer to NK cells the capacity to kill virus-infected or tumor cells [49,50]; one of these receptors is represented by NKG2D, which can recognize different ligands including MICA molecules; thus, NKG2D could have a significant role in anti-tumor immune response [21-23].